Event 14 Oct. 2022
Curtis Provides Capacity Training to the Government of Uganda
Event 21 Sep. 2022
Kalidou Gadio Speaks at AIEN 2022 International Energy Summit
Event 06 Jun. 2023
Partner Borzu Sabahi Speaks on Panel in Tashkent Law Spring International Legal Forum in the Republic of Uzbekistan
News 15 May. 2023
Curtis represents e-commerce retailer in its fight to recover monies withheld by PayPal, the global payment giant
Article 08 Jun. 2023
Jonathan Walsh, Elisa Botero and Vadim Belinskiy Publish Article in Law360 on Meta’s EU Data Privacy Transfer Fine
Event 08 May. 2023
Partner Irene Petrelli to Participate in ICC YAAF Event
Event 07 Jun. 2023
Elisa Botero Speaks on Latin America’s H2 Potential at AIEN’s International Energy Summit
Event 23 May. 2023
Partners Luciana Ricart and Fernando Tupa Will Teach a Workshop on Hearings in Investment Arbitration for Arbanza School of Arbitration’s Online Program
Event 03 May. 2023
Dr. Borzu Sabahi to Speak at ICSID-ADGM Joint Conference: Investment Protection and Armed Conflict
Event 19 Mar. 2023
Sebastiano Nessi speaks at Bahrain Business and Legal Landscape Conference
Event 01 Jun. 2023
Curtis Environmental Chair Charles Howland to Moderate Panel Discussion on Latest Developments in Environmental Due Diligence at ABA Masterclass on Environmental Transactions
News 25 May. 2023
Curtis Files SCOTUS Amicus Brief for Distinguished Law Professors in First Amendment Retaliatory Arrest Case
News 06 Mar. 2023
Russia Sanctions at the First Anniversary: An Overview of Current Sanctions in the US, UK, and EU and How Global Companies Can Navigate Evolving and Conflicting Sanctions Regimes
Client Alert 30 Aug. 2022
The EU Adopts the “Maintenance and Alignment” Sanctions Package
Client Alert 24 Jun. 2021
Update on Virtual Notarization (Executive Order 202.7) During the COVID-19 (Coronavirus) Pandemic (Updated: June 24, 2021) — U.S. Insight
Update on Virtual Witnessing (New York Executive Order 202.14) During The COVID-19 (Coronavirus) Pandemic (Updated: June 24, 2021) — U.S. Insight
Companies operating in the pharmaceutical and related sectors such as healthcare must grapple with cutting-edge scientific development as well as shifting regulatory regimes, which complicate corporate mergers and acquisitions, managing intellectual property portfolios and patents, and litigating disputes. The ethical dimension makes it imperative to have the right legal advice.
Curtis provides a wide range of legal services to clients in the pharmaceutical sector. Our pharmaceutical attorneys advise manufacturers, funds and institutions on transactions and disputes involving branded and generic pharmaceuticals, biotechnology equipment, clinical systems, nanotechnology, medical software and prescription drugs, drug delivery and drug packaging.
We have advised on a diverse range of mergers and acquisitions and other transactions.
The wider Curtis team includes experts in the field of healthcare compliance, as well as former medical doctors and lawyers with experience in pharmaceutical patent and regulatory (Hatch-Waxman) litigation in the U.S.
This has enabled Curtis to develop a range of experience in the pharmaceutical sector, ranging from healthcare issues to compliance and specialist intellectual property. Our healthcare attorneys have also advised on the development and financing of healthcare infrastructure projects such as hospitals in many countries, by way of PPI as well as traditional project finance and Islamic finance.
Intellectual Property Litigation
Commercial Disputes - Litigation
Legal 500 USA, 2019
Legal 500: USA M&A(Middle-Market) 2017
Legal 500 USA 2019